Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
CONCLUSIONS: Although there was an apparent decrease in relative efficacy to prevent arterial thromboembolism in the upper range of CrCl, the safety and net clinical benefit of HDER compared with warfarin are consistent across the range of renal function.
CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00781391.
PMID: 27358434 [PubMed - in process]
Source: Circulation - Category: Cardiology Authors: Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM, Braunwald E Tags: Circulation Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Chronic Kidney Disease | Clinical Trials | Coumadin | Epidemiology | Heart Attack | Stroke | Study | Thrombosis | Urology & Nephrology | Warfarin